Xconomy: San Francisco blog main News, Articles and Opinions

Search Results for “”

SQZ Biotech Lines Up an IPO on the NYSE to Fund Cell Therapy R&D
Frank Vinluan·5:39 pm
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
Frank Vinluan·11:08 am
In RNAi Move, Takeda Fronts $300M to Team Up on Arrowhead Liver Drug
Frank Vinluan·1:11 pm
BIO Launches ‘Biotech Votes’ Campaign to Encourage Registration and Informed Voting
Editors·9:41 am
Scribe Therapeutics Sets Out to Write CRISPR Gene Editing’s Next Chapter
Frank Vinluan·4:02 pm
Federation Bio Bags $50M to Engineer New Approach to Microbiome Drugs
Frank Vinluan·7:30 am
Bristol Myers to Buy MyoKardia, FDA-Ready Heart Disease Drug for $13.1B
Frank Vinluan·12:43 pm
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
Frank Vinluan·1:56 pm
Pfizer Pumps $200M Into CStone for Rights to PD-L1 Cancer Drug in China
Frank Vinluan·12:43 pm
With Phase 2 Data in Hand, Ovid Eyes Multiple Pivotal Trials for Epilepsy Drug
Frank Vinluan·8:00 am
Praxis Precision Medicines Leads Way as Three More Biotechs Prep IPOs
Frank Vinluan·5:34 pm
Galecto Picks Up $64M as Plans for Fibrosis Clinical Trials Move Forward
Frank Vinluan·4:36 pm
Bio Roundup: Grail Acquisition, Libra’s Launch, Tau Trial Results & More
Frank Vinluan·10:41 am
Monte Rosa Raises $96M for “Glue-Based” Protein Degrading Drugs
Frank Vinluan·2:49 pm
Xconomy Awards On-Demand ‘Meet the Finalists’ Webcast Series Continues This Week
Editors·10:28 am
Illumina to Acquire Cancer Diagnostics Developer Grail in $8B Deal
Frank Vinluan·9:48 am
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
Frank Vinluan·11:34 am
Moderna CMO Talks COVID-19 Vaccine at the Xcelerate Keynote Series
Editors·8:50 am
Neogene Therapeutics Grabs $110M to Tackle Solid Tumors With Cell Therapy
Frank Vinluan·7:02 pm
Unity Bio Restructuring Cuts 30% of Staff, Keeps Focus on Eye Drug
Frank Vinluan·10:49 am

Page 1 of 307